Molecular engineering of a therapeutic antibody for Blo t 5–induced allergic asthma - 27/09/17
Doi : 10.1016/j.jaci.2016.10.028
J.H. Sherlynn Chan, BSc(Hons) a, b, c, Yen Leong Chua, MSc a, b, Hong Yong Peh, BSc(Hons) a, d, Vojislav Jovanovic, PhD a, Nicholas R.J. Gascoigne, PhD b, W. S. Fred Wong, PhD a, d, Fook Tim Chew, PhD e, Brendon J. Hanson, PhD f, David M. Kemeny, PhD, FRCPath a, b, Paul A. MacAry, PhD a, b, c 
a Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore
b Department of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
c NUS Graduate School for Integrative Sciences and Engineering (NGS), National University of Singapore, Singapore
d Department of Pharmacology, Yong Loo Lin School of Medicine, National University Health System, Singapore
e Department of Biological Sciences, National University of Singapore, Singapore
f Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore
| This work was supported by the National Research Foundation (grant no. NRF370062-HUJ-NUS). S.J. H.C. was supported by the NUS Graduate School for Integrative Sciences and Engineering (NGS) scholarship. |
|
| Disclosure of potential conflict of interest: J. H. Sherlynn Chan, V. Jovanovic, and P. A. MacAry receive grant support from the National Research Foundation, Singapore. N. R. J. Gascoigne receives grant support from the National Medical Research Council and Ministry of Education (MOE) and travel support from the Japan Society of Immunology and European Molecular Biology Organization (EMBO). F. T. Chew receives grant support from the Singapore Ministry of Education Academic Research Fund, the Singapore Immunology Network, the National Medical Research Council (Singapore), and the Agency for Science Technology and Research (A*STAR) (Singapore); serves as a consultant for Sime Darby Technology Centre, First Resources Ltd, and Olam International; and is an employee of National University of Singapore. B. J. Hanson is an employee of National University of Singapore Life Sciences Institute. D. M. Kemeny receives grant support from the National Medical Research Council. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 5
P. 1705 - mai 2017 Retour au numéro
Article précédent
- Rapamycin preferentially inhibits human IL-5+ TH2-cell proliferation via an mTORC1/S6 kinase-1–dependent pathway
- Yuzhi Yin, Alyssa Mitson-Salazar, Daniel L. Wansley, Satya P. Singh, Calman Prussin
- Liver transplantation in patients with primary antibody deficiency
- Silje F. Jørgensen, Magnhild E. Macpherson, Kristian Bjøro, Tom H. Karlsen, Henrik M. Reims, Krzysztof Grzyb, Bjarte Fosby, Børre Fevang, Pål Aukrust, Ingvild Nordøy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?